论文部分内容阅读
目的:评价CPVF方案治疗晚期食管癌的疗效和安全性,并和PVB经典方案在疗效、不良反应和药物经济学上相比较。方法:CPVF方案:VDS3mg/m2d1、8,CF25mg/m2d1～5,5-FU0.5/m2d1～5,DDP25mg/m2d1～3,每4周重复;2个周期后评价疗效。结果:42例中,有效率为54.8%(95%CI:43.7%～69.9%),中位生存期10个月,1年和2年生存率分别为40.5%和12.1%。不良反应主要是白细胞下降和恶心、呕吐,分别为55.5%和34.5%;其中Ⅲ/Ⅳ级各为12.7%和17.2%。结论:CPVF方案治疗晚期食管癌疗效满意,不良反应可耐受,推荐临床应用。
OBJECTIVE: To evaluate the efficacy and safety of CPVF regimen in the treatment of advanced esophageal cancer and to compare its efficacy, adverse reactions and pharmacology with the classical PVB regimen. Methods: CPVF program: VDS3mg / m2d1,8, CF25mg / m2d1 ~ 5,5-FU0.5 / m2d1 ~ 5, DDP25mg / m2d1 ~ 3, repeated every 4 weeks; 2 cycles after the evaluation of efficacy. Results: In 42 cases, the effective rate was 54.8% (95% CI: 43.7% -69.9%). The median survival time was 10 months. The 1-year and 2-year survival rates were 40.5% and 12.1% respectively. The main adverse reactions were leukopenia and nausea and vomiting, which were 55.5% and 34.5% respectively. The grade Ⅲ / Ⅳ were 12.7% and 17.2% respectively. Conclusion: The CPVF regimen is effective in treating advanced esophageal cancer and the adverse reactions are tolerable. Clinical application is recommended.